Overview

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

Status:
Completed
Trial end date:
2019-04-26
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
Phase:
Phase 2
Details
Lead Sponsor:
Eisai Co., Ltd.